- Home
- KYMR vs NCLH Comparison
KYMR vs NCLH Comparison
Compare KYMR & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYMR | NCLH |
|---|---|---|
| Founded | 2015 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.9B |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | KYMR | NCLH |
|---|---|---|
| Price | $104.20 | $20.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 17 |
| Target Price | ★ $107.72 | $24.76 |
| AVG Volume (30 Days) | 558.9K | ★ 14.4M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | $39,211,000.00 | ★ $5,396,175,000.00 |
| Revenue This Year | $10.61 | $9.96 |
| Revenue Next Year | $8.17 | $6.60 |
| P/E Ratio | ★ N/A | $85.91 |
| Revenue Growth | N/A | ★ 10.71 |
| 52 Week Low | $36.88 | $14.53 |
| 52 Week High | $130.05 | $27.18 |
Technical Indicators
Market Signals| Indicator | KYMR | NCLH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 75,000). It operates 35 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 16 passenger vessels on order among its brands through 2037, representing 43,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.